Charlot Biosciences - Customer Brochure
Charlot Biosciences is commercializing innovative physics to study life. We are introducing a novel live cell analysis platform to the world of cell sorting and analysis. The technology is called cellPhoresis™. The Technology: Our platform has the unique ability to rapidly fractionate and sort cells based on biophysical properties.allowing researchers to study important differences between living cells only identifiable with genetic sequencing or protein sequencing. Being an agnostic approach to cell separation, we can support wide range of applications ranging from CRISPR gene editing verification, drug discovery for diseases like cancer and Alzheimer’s, and diagnostic assay development. The technology is backed by exclusive IP from ASU, Cal-Tech, and Charlot Biosciences. The platform separates cells based on inherent biophysical properties (external properties as well as internal structure and content). This approach enables the identification of important differences between live cells without labeling or destructive alteration. This benefit saves labs both time and money. The technology has already been validated in rapid pathogen identification and used for tracking human embryonic stem cell differentiation into various neural populations. Our interested partners have cited the value our cellPhoresis™ platform provides to develop new classes of molecular assays that help researchers and pharmaceutical companies screen for unintended side effects of gene therapy. Our affordable technology also enables enrichment of cells based on functional differences prior to nucleic acid purification and NGS. This approach enables faster discover of new biomarkers associated with complex disease.
Charlot Biosciences is commercializing innovative physics to study life. We are introducing a novel live cell analysis platform to the world of cell sorting and analysis. The technology is called cellPhoresis™.
The Technology:
Our platform has the unique ability to rapidly fractionate and sort cells based on biophysical properties.allowing researchers to study important differences between living cells only identifiable with genetic sequencing or protein sequencing. Being an agnostic approach to cell separation, we can support wide range of applications ranging from CRISPR gene editing verification, drug discovery for diseases like cancer and Alzheimer’s, and diagnostic assay development.
The technology is backed by exclusive IP from ASU, Cal-Tech, and Charlot Biosciences. The platform separates cells based on inherent biophysical properties (external properties as well as internal structure and content). This approach enables the identification of important differences between live cells without labeling or destructive alteration. This benefit saves labs both time and money.
The technology has already been validated in rapid pathogen identification and used for tracking human embryonic stem cell differentiation into various neural populations. Our interested partners have cited the value our cellPhoresis™ platform provides to develop new classes of molecular assays that help researchers and pharmaceutical companies screen for unintended side effects of gene therapy. Our affordable technology also enables enrichment of cells based on functional differences prior to nucleic acid purification and NGS. This approach enables faster discover of new biomarkers associated with complex disease.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
How can we<br />
accelerate<br />
your research?
Change language